| Preface |
|
xv | |
| Contributors |
|
xi | |
| Part I Clinical Metabolomics And Lipidomics |
|
|
1 Metabolomics as a Tool to Understand Pathophysiological Processes |
|
|
3 | (26) |
|
|
|
|
|
2 Metabolomics in Immunology Research |
|
|
29 | (16) |
|
|
| Part II LC-MS-Based Metabolomics |
|
|
3 LC-MS-Based Metabolomics of Biofluids Using All-Ion Fragmentation (AIF) Acquisition |
|
|
45 | (14) |
|
|
|
|
|
|
|
|
|
4 Lipid Mediator Metabolomics Via LC-MS/MS Profiling and Analysis |
|
|
59 | (14) |
|
|
|
|
|
|
|
|
|
5 UHPSFC/ESI-MS Analysis of Lipids |
|
|
73 | (10) |
|
|
|
|
|
6 LC-MS/MS Analysis of Lipid Oxidation Products in Blood and Tissue Samples |
|
|
83 | (10) |
|
|
|
|
|
7 Serum Testosterone by Liquid Chromatography Tandem Mass Spectrometry for Routine Clinical Diagnostics |
|
|
93 | (10) |
|
|
|
|
|
|
|
8 LC-MS/MS Analysis of Bile Acids |
|
|
103 | (8) |
|
|
|
|
|
9 LC-MS/MS Analysis of Triglycerides in Blood-Derived Samples |
|
|
111 | (12) |
|
|
|
|
|
|
|
10 LC-MS/MS Analysis of the Epoxides and Diols Derived from the Endocannabinoid Arachidonoyl Ethanolamide |
|
|
123 | (12) |
|
|
|
|
|
|
|
|
|
|
|
11 Sphingolipid Analysis in Clinical Research |
|
|
135 | (28) |
|
|
|
|
|
|
|
|
|
12 Shotgun Lipidomics Approach for Clinical Samples |
|
|
163 | (12) |
|
|
|
|
|
13 Establishing and Performing Targeted Multi-residue Analysis for Lipid Mediators and Fatty Acids in Small Clinical Plasma Samples |
|
|
175 | (38) |
|
|
|
|
|
14 Chemical Isotope Labeling LC-MS for Human Blood Metabolome Analysis |
|
|
213 | (14) |
|
|
|
|
|
15 Direct Infusion-Tandem Mass Spectrometry (DI-MS/MS) Analysis of Complex Lipids in Human Plasma and Serum Using the Lipidyzer Platform |
|
|
227 | (12) |
|
|
| Part III GC-MS-Based Metabolomics |
|
|
16 Exploratory GC/MS-Based Metabolomics of Body Fluids |
|
|
239 | (8) |
|
|
|
|
|
|
|
17 GC-MS Analysis of Short-Chain Fatty Acids in Feces, Cecum Content and Blood Samples |
|
|
247 | (10) |
|
|
|
|
|
|
|
|
|
|
|
18 GC-MS Analysis of Medium- and Long-Chain Fatty Acids in Blood Samples |
|
|
257 | (10) |
|
|
|
|
|
|
|
|
|
|
|
19 Analysis of Oxysterols |
|
|
267 | (10) |
|
|
|
|
|
20 Analysis of Metabolites from the Tricarboxylic Acid Cycle for Yeast and Bacteria Samples Using Gas Chromatography Mass Spectrometry |
|
|
277 | (6) |
|
|
|
|
|
|
|
21 GC-MS Analysis of Lipid Oxidation Products in Blood, Urine and Tissue Samples |
|
|
283 | (12) |
|
|
|
|
| Part IV CE-MS-Based Metabolomics |
|
|
22 Metabolic Profiling of Urine by Capillary Electrophoresis-Mass Spectrometry Using Non-covalently Coated Capillaries |
|
|
295 | (10) |
|
|
|
23 CE-MS for the Analysis of Amino Acids |
|
|
305 | (12) |
|
Karina Trevisan Rodrigues |
|
|
Marina Franco Maggi Tavares |
|
|
|
| Part V NMR-Based Metabolomics |
|
|
24 NMR Analysis of Fecal Samples |
|
|
317 | (12) |
|
|
|
|
|
|
|
25 Quantitative Analysis of Central Energy Metabolism in Cell Culture Samples |
|
|
329 | (16) |
|
|
| Part VI Maldi-Based Techniques And Mass Spectrometry Imaging Of Clinical Samples |
|
|
26 Mass Spectrometry Imaging of Metabolites |
|
|
345 | (16) |
|
|
|
|
| Part VII Study Design, Data Analysis And Bioinformatics |
|
|
27 Quality-Assured Biobanking: The Leiden University Medical Center Model |
|
|
361 | (10) |
|
|
|
|
|
28 Extracting Knowledge from MS Clinical Metabolomic Data: Processing and Analysis Strategies |
|
|
371 | (14) |
|
|
|
|
| Perspectives |
|
385 | (2) |
| Index |
|
387 | |
